UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group

International journal of radiation oncology, biology, physics, 2015-12, Vol.93 (5), p.1071-1076

2015

Volltextzugriff (PDF)

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

Cancer medicine (Malden, MA), 2019-10, Vol.8 (14), p.6437-6448

2019

Volltextzugriff (PDF)

Pediatric solid tumors and associated cancer predisposition syndromes: Workup, management, and surveillance. A summary from the APSA Cancer Committee

Journal of pediatric surgery, 2022-03, Vol.57 (3), p.430-442

2022

Volltextzugriff (PDF)

Update on rhabdomyosarcoma

Seminars in pediatric surgery, 2012-02, Vol.21 (1), p.68-78

2012

Volltextzugriff (PDF)

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5182-5188

2009

Volltextzugriff (PDF)

Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3226-3232

2013

Volltextzugriff (PDF)

Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committee

Journal of pediatric surgery, 2020-11, Vol.55 (11), p.2260-2272

2020

Volltextzugriff (PDF)

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1304-1311

2011

Volltextzugriff (PDF)

Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study

International journal of radiation oncology, biology, physics, 2012-06, Vol.83 (2), p.720-726

2012

Volltextzugriff (PDF)

Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: Combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee

International journal of cancer, 2011-03, Vol.128 (5), p.1232-1239

2011

Volltextzugriff (PDF)

Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group

International journal of radiation oncology, biology, physics, 2011-07, Vol.80 (4), p.1151-1157

2011

Volltextzugriff (PDF)

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3705-3711

2009

Volltextzugriff (PDF)

CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma

Clinical cancer research, 2003-08, Vol.9 (8), p.3105-3114

2003

Volltextzugriff (PDF)

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2019-11, Vol.37 (31), p.2866-2874

2019

Volltextzugriff (PDF)

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2016-01, Vol.34 (2), p.117-122

2016

Volltextzugriff (PDF)

Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis

Pediatric Blood & Cancer, 2005-11, Vol.45 (6), p.796-801

2005

Volltextzugriff (PDF)

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

Pediatric blood & cancer, 2022-04, Vol.69 (4), p.e29511-n/a

2022

Volltextzugriff (PDF)

Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Pediatric blood & cancer, 2024-11, Vol.71 (11), p.e31303-n/a

2024

Volltextzugriff (PDF)

Abdominal Tumors: Wilms, Neuroblastoma, Rhabdomyosarcoma, and Hepatoblastoma

The Surgical clinics of North America, 2022-10, Vol.102 (5), p.715-737

2022

Volltextzugriff (PDF)

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Cancer, 2019-01, Vol.125 (2), p.290-297

2019

Volltextzugriff (PDF)

Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft‐Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe

Pediatric blood & cancer, 2023-05, Vol.70 (5), p.e28601-n/a

2023

Volltextzugriff (PDF)

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

Cancer, 2019-09, Vol.125 (18), p.3242-3248

2019

Volltextzugriff (PDF)

Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee

Journal of pediatric surgery, 2020-10, Vol.55 (10), p.1987-1995

2020

Volltextzugriff (PDF)

Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group

Cancer, 2021-01, Vol.127 (2), p.275-283

2021

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(136)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

Pediatric solid tumors and associated cancer predisposition syndromes: Workup, management, and surveillance. A summary from the APSA Cancer Committee

Update on rhabdomyosarcoma

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee

Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committee

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group D9602 Study

Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Pediatric inflammatory myofibroblastic tumor: Anaplastic lymphoma kinase (ALK) expression and prognosis

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Abdominal Tumors: Wilms, Neuroblastoma, Rhabdomyosarcoma, and Hepatoblastoma

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft‐Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe

Increased local failure for patients with intermediate‐risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group

Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee

Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group

Suchergebnisse filtern